Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,355,181 papers from all fields of science
Search
Sign In
Create Free Account
Ibrutinib 140 MG Oral Capsule [Imbruvica]
Known as:
Imbruvica 140 MG Oral Capsule
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
9 relations
Croscarmellose Sodium
Ibrutinib
Imbruvica
Magnesium stearate
Expand
Broader (2)
Ibrutinib 140 MG Oral Capsule
Ibrutinib Oral Capsule [Imbruvica]
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Horizon Scanning in Oncology Ibrutinib ( Imbruvica ® ) in combination with rituximab for the treatment of Waldenström ’ s macroglobulinemia
2019
Corpus ID: 195060994
2018
2018
Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenström’s macroglobulinaemia
L. McGahan
2018
Corpus ID: 86812099
Constitutive Bruton tyrosine kinase (BTK) activation is associated with B-cell proliferation and lymphoma progression. Ibrutinib…
Expand
2017
2017
Ibrutinib „first line“ in der CLL-Therapie
M. Mundt
Info Onkologie
2017
Corpus ID: 79564160
In einer Phase-III-Studie wurde der Brutontyrosinkinaseinhibitor Ibrutinib (Imbruvica®) als Erstlinientherapie für CLL-Patienten…
Expand
2016
2016
Ibrutinib repurposing: from B-cell malignancies to solid tumors
D. Massó-Vallés
,
T. Jauset
,
L. Soucek
Oncoscience
2016
Corpus ID: 14502913
Ibrutinib (Imbruvica®, also known as PCI-32765) is a first-in-class, irreversible small-molecule inhibitor of Bruton's Tyrosine…
Expand
2016
2016
ibrutinib (IMBRUVICA°) and Waldenström's macroglobulinaemia.
Prescrire international
2016
Corpus ID: 58620922
The only available trial, a non-comparative study with 63 patients, failed to determine the efficacy of ibrutinib. In contrast…
Expand
Review
2015
Review
2015
Targets for Ibrutinib Beyond B Cell Malignancies
A. Berglöf
,
A. Hamasy
,
+7 authors
C. I. Smith
Scandinavian Journal of Immunology
2015
Corpus ID: 14721043
Ibrutinib (Imbruvica™) is an irreversible, potent inhibitor of Bruton's tyrosine kinase (BTK). Over the last few years, ibrutinib…
Expand
Review
2015
Review
2015
Ibrutinib: A Review of Its Use in Patients with Mantle Cell Lymphoma or Chronic Lymphocytic Leukaemia
Esther S. Kim
,
Sohita Dhillon
Drugs
2015
Corpus ID: 5555318
Ibrutinib (Imbruvica®) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton’s tyrosine kinase (BTK…
Expand
2015
2015
Abstract 251: Combining Ibrutinib with immune checkpoint blockade to induce therapeutic antitumor immune response in solid tumors
Idit Sagiv-Barfi
,
H. Kohrt
,
D. Czerwinski
,
P. Ng
,
B. Chang
,
R. Levy
2015
Corpus ID: 78543162
The ability of T-cell responses to effectively attack tumors is restricted by multiple negative checkpoint regulators. Monoclonal…
Expand
Review
2014
Review
2014
Ibrutinib: First Global Approval
F. Cameron
,
M. Sanford
Drugs
2014
Corpus ID: 34700100
Ibrutinib (Imbruvica™) is a small molecule, first-in-class, once-daily, orally available, Bruton’s tyrosine kinase inhibitor that…
Expand
2014
2014
Ibrutinib (Imbruvica®) for relapsed or refractory chronic lymphocytic leukaemia
A. Nachtnebel
,
J. Breuer
2014
Corpus ID: 67965722
Ibrutinib is a first-in-class, small-molecule inhibitor of Bruton’s Tyrosine Kinase (BTK). Based on the results of the RESONATE…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE